- TRADE NAME: Rhopressa (Aerie)
- INDICATIONS: Reduction of elevated intraocular pressure in open angle glaucoma or ocular hypertension
- CLASS: Rho kinase inhibitor
- HALF-LIFE: N/A
- FDA APPROVAL DATE: 12/18/2017
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known - PREGNANCY: No available data to inform drug-associated risk
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
